June 9, 2020 07:14 AM EDT

CSL Behring snaps up a closely-held biotech partner and its IL-6 drug — for transplant rejection

Amber Tong

Having closely watched and funded a Canadian biotech partner’s IL-6 drug for two and a half years, CSL Behring is snapping it all up. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Struggling biotechs succumb to icy market, as money dries up and clinical bets don’t pay off

In a first, Sarepta announces platform technology designation for gene therapy vector

Anne Wojcicki and Regeneron set to duke it out in restarted 23andMe auction

Exclusive: Tech VC Amplify raises $200M for first biotech fund, hires Elliot Hershberg as new partner

Exclusive: After cutting most staff, Casma eyes path to clinic with its first autophagy-boosting drug

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...